The era of nanotechnology and omics sciences

Li, Wen

doi:10.18088/ejbmr.1.1.2015.pp1-2

Cited by 7 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, improved ‘personalised’ risk prediction models could allow substantial healthcare savings by improving chances for early detection and management of cancer [ 12 ]. Second, although niche oncology drugs are expensive, the costs of biomarker detection are diminishing (currently between $100 and $5000 per patient) [ 87 , 88 ], notably owing to the progress made in the fields of bioengineering and the increased use of nanotechnologies [ 89 ]. Third, contrary to personalized drug development, the use of genomic tests to adjust the dosage of an already approved medication or to substitute an approved drug for another seem to be intuitively very cost efficient.…”

Section: Existing Standards Challenged New Standards Neededmentioning

confidence: 99%

Integrating precision cancer medicine into healthcare—policy, practice, and research challenges

et al. 2016

View full text Add to dashboard Cite

Precision medicine (PM) can be defined as a predictive, preventive, personalized, and participatory healthcare service delivery model. Recent developments in molecular biology and information technology make PM a reality today through the use of massive amounts of genetic, ‘omics’, clinical, environmental, and lifestyle data. With cancer being one of the most prominent public health threats in developed countries, both the research community and governments have been investing significant time, money, and efforts in precision cancer medicine (PCM). Although PCM research is extremely promising, a number of hurdles still remain on the road to an optimal integration of standardized and evidence-based use of PCM in healthcare systems. Indeed, PCM raises a number of technical, organizational, ethical, legal, social, and economic challenges that have to be taken into account in the development of an appropriate health policy framework. Here, we highlight some of the more salient issues regarding the standards needed for integration of PCM into healthcare systems, and we identify fields where more research is needed before policy can be implemented. Key challenges include, but are not limited to, the creation of new standards for the collection, analysis, and sharing of samples and data from cancer patients, and the creation of new clinical trial designs with renewed endpoints. We believe that these issues need to be addressed as a matter of priority by public health policymakers in the coming years for a better integration of PCM into healthcare.

show abstract

Section: Existing Standards Challenged New Standards Neededmentioning

confidence: 99%

Integrating precision cancer medicine into healthcare—policy, practice, and research challenges

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This characteristic makes Pt(IV) drugs ideal prodrugs for cancer therapy. In addition to that, nanoparticle-mediated drug delivery also offers a possible solution by loading prodrugs for drug delivery. − …”

mentioning

confidence: 99%

Turning Ineffective Transplatin into a Highly Potent Anticancer Drug via a Prodrug Strategy for Drug Delivery and Inhibiting Cisplatin Drug Resistance

Jiang

Cao

et al. 2016

Bioconjugate Chem.

View full text Add to dashboard Cite

Clinically ineffective transplatin is highly potent against cancer cells when transformed into a transplatin(IV) prodrug nanoparticle. Herein, a hydrophobic transplatin(IV) was synthesized by H2O2-oxidization of transplatin and attachment of two hydrophobic aliphatic chains. Transplatin(IV) was subsequently encapsulated by a biodegradable amphiphilic copolymer, MPEG-PLA, forming a well-defined spherical micelles (M(TransPt)). Transplatin(IV) was protected efficiently and could be released under a simulated cancerous intracellular condition. Compared to the cisplatin and transplatin, M(TransPt) showed the highest Pt uptake and a clathrin-dependent endocytosis pathway. Most importantly, M(TransPt) displayed a nanomolar IC50 on A2780 cells and a great potency on cisplatin resistant A2780DDP cell line. Overall, this nanoplatform for delivering trans-geometry platinum(IV) drug exhibits excellent characteristics for enhancing efficacy and overcoming cisplatin drug resistance, and holds a strong promise for clinical use in the near future.

show abstract